Pilot trial of cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide + antiretrovirals + G-CSF + erythropoietin in AIDS-associated non-Hodgkin's lymphoma: CALGB 9155 (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Pilot trial of cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide + antiretrovirals + G-CSF + erythropoietin in AIDS-associated non-Hodgkin's lymphoma: CALGB 9155 (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 16:A195 1997. Unique Identifier : AIDSLINE MED/97621067
Feigal EG; Petroni GR; Freter C; Johnson JL; Barcos M; Peterson BA; CALGB, Chicago, IL

Abstract: Forty-six patients with previously untreated histologically confirmed intermediate and high-grade AIDS-associated non-Hodgkin's lymphoma (NHL) entered CALGB's first trial in AIDS-malignancies evaluating escalating doses of cyclophosphamide(C), doxorubicin(H), vincristine(O), prednisone(P), etoposide(E), antiretrovirals, opportunistic infection therapy, and growth factor support. Data on the safety/efficacy of combination chemotherapy with one of the more potent and myelosuppressive antiretrovirals, was needed. The primary objective was to evaluate toxicity with secondary objectives to describe response, and time to progression. Median CD4 count at entry was less than 200. Dosage is presented in a table. The treatment consisted of C, H, and O (1.4 mg/m2 ) IV day 1; E IV days 1,2,3; P 100 mg/day days 1- 5. Zidovudine 500 to 600 mg/day. G-CSF SC 5 mcg/kg/d days 5-20; Erythropoietin SC or IV 100 IU/kg 3 times weekly days 5-20. All patients received PCP and fungal prophylaxis; Leptomeningeal prophylaxis: day 1 of cycle 3 to patients with bone marrow involvement. Grade 4 leukopenia was milder in cohort 1 (33%), vs cohorts 2- 6 (67-100%) however grade 4 granulocytopenia was similar in all cohorts (cohort 1: 67% vs cohorts 2-6: 57% - 100% ). Anemia also did not have a clear dose-response relationship across cohorts. 4 fatal infections appeared to be related to hematologic toxicity (cohorts 4-6). There was an 80% objective response rate (CRs + PRs, n = 39 evaluable) for the overall study with responses in all cohorts except cohort 6. Concomitant treatment of HIV and NHL-lymphoma is well tolerated. New studies are evaluating concomitant protease inhibitor combinations, biologic and cytotoxic therapies. (C) American Society of Clinical Oncology 1997

Keywords: *Anti-HIV Agents/THERAPEUTIC USE *Antineoplastic Agents, Combined/THERAPEUTIC USE *Erythropoietin/THERAPEUTIC USE *Granulocyte Colony-Stimulating Factor/THERAPEUTIC USE *Lymphoma, AIDS-Related/DRUG THERAPY
971130
M97B1214

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .